NCT05239260 is a clinical trial of CMR in NAFLD/MAFLD, sponsored by Medical University of Vienna.

Who is sponsoring NCT05239260?

NCT05239260 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT05239260?

Interventions in NCT05239260: CMR.

What condition does NCT05239260 study?

NCT05239260 studies NAFLD/MAFLD, Liver Fibrosis, CMR.

Is NCT05239260 still recruiting?

NCT05239260 is currently status unknown. Last updated 14 February 2022.

Last reviewed 2022-02-14 · How we verify

NCT05239260

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.

Status unknown Last updated 14 February 2022

What this trial tests

trial testing CMR in NAFLD/MAFLD in 150 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
1 May 2022

1 January 2023

Quick facts

Lead sponsor	Medical University of Vienna
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 February 2022
Primary completion	1 May 2022
Estimated completion	1 January 2023
Sites	1 location across Austria

Drugs / interventions tested

Conditions studied

NAFLD/MAFLD — all drugs for NAFLD/MAFLD →
Liver Fibrosis — all drugs for Liver Fibrosis →
CMR — all drugs for CMR →

Sponsor

Medical University of Vienna

Who can join

Eligibility, any sex, with NAFLD/MAFLD or Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CMR

Trials testing the same drug.

NCT07131111 — Impact of Aortic Geometry on Vascular Remodeling After Stent Implantation in Coarctation of the Aorta · not yet recruiting
NCT06780241 — Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease · recruiting
NCT06323811 — Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics · NA · unknown
NCT06266858 — Multimodality Imaging Assessment of the Severity of Mitral Regurgitation · NA · unknown
NCT05322109 — Cardiac Magnetic Resonance Tomography for Heart Failure With Preserved Ejection Fraction · completed

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05239260 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing